References
- AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530–47
- Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003; 170: 498–502
- Schulman CC, Lock TMTW, Buzelin J-M, Boeminghaus F, Stephenson TP, Talja M, et al. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 2001; 168: 1358–63
- Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525–30
- Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 1995; 45: 406–13
- Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M. 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 2004; 45: 620–7
- Chapple CR. Clinical study of benign prostatic disease, current concepts and future prospects: randomized controlled trials versus real life practice. Curr Opin Urol 2003; 13: 1–5
- Mishra V, Emberton M. To what extent do real life practice studies differ from randomized controlled trials in lower urinary tract symptoms/benign prostatic hyperplasia?. Curr Opin Urol 2006; 16: 1–4
- Homma Y, Kawabe K, Tsukamoto T, Yamaguchi O, Okada K, Aso Y, et al. Estimate criteria for diagnosis and severity in benign prostatic hyperplasia. Int J Urol 1996; 3: 261–6
- Homma Y, Kawabe K, Tsukamoto T, Yamaguchi O, Okada K, Aso Y, et al. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int J Urol 1996; 3: 267–73
- Masumori N, Sato Y, Itoh N, Tsukamoto T, Sakai S, Aoyama T, et al. Clinical efficacy of naftopidil for benign prostatic hyperplasia—the effect on storage symptoms. Jpn J Urol Surg 2004; 17: 335–44
- Takei R-I, Ikegaki I, Shibata K, Tusjimoto G, Asano T. Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors. Jpn J Pharmacol 1999; 79: 447–54
- Nasu K, Moriyama N, Kawabe K, Tusjimoto G, Murai M, Tanaka T, et al. Quantification and distribution of α1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996; 119: 797–803
- Malloy BJ, Price DT, Price RR, Bienstock AM, Dole MK, Funk BL, et al. 1 adrenergic receptor subtypes in human detrusor. J Urol 1998; 160: 937–43
- Smith MS, Schambra UB, Wilson KH, Page SO, Schwinn DA. α1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding α1-adrenergic receptor subtypes at four distinct levels. Mol Brain Res 1999; 63: 254–61
- Yamaguchi O, Fukaya Y, Shiraiwa Y, Kaneko S, Yachiku S, Honma Y, et al. Dose-dependent effects and clinical usefulness of naftopidil (KT-611) on urinary obstruction caused by benign prostatic hyperplasia—double-blind comparative study compared with placebo. Clin Rep 1997; 31: 1315–60
- Tanaka Y, Masumori N, Aoki M. Clinical follow-up of patients treated with α1-blockers as initial treatment for benign prostatic hyperplasia. Jpn J Urol Surg 2004; 17: 681–4
- De la Rosette JJMCH, Kortmann BBM, Rossi C, Sonke GS, Floratos DL, Kiemeney LALM. Long-term risk of re-treatment of patients using α-blockers for lower urinary tract symptoms. J Urol 2002; 167: 1734–9
- McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387–98
- Mochtar CA, Kiemeney LALM, Laguna MP, van Riemsdijk MM, Barnett GS, Debruyne FMJ, et al. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting. Urology 2005; 65: 300–5
- Tanaka Y, Masumori N, Itoh N, Tsukamoto T, Furuya S, Ogura H. The prediction of bladder outlet obstruction with prostate volume, maximum flow rate, residual urine and the International Prostate Symptom Score in patients with lower urinary tract symptoms. Acta Urol Jpn 2001; 47: 843–7
- Ichioka K, Ohara H, Terada N, Matsui Y, Yoshimura K, Terai A, et al. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int J Urol 2004; 11: 870–5